Clinical trials: Mild to Moderate COVID-19
Healthy Volunteers, COVID-19
Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19
This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled study to assess the safety, tolerability, and pharmacokinetics (PK) of IGM-6268 administered intranasally and intraorally in healthy volunteers and…
- Trial name
- NCT05184218
- Testing
- IGM-6268
- Where
- South Africa
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- IGM Biosciences, Inc.
Infection of Upper Respiratory Tract Caused by 2019-nCoV
SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients
Evaluating the efficacy and safety of SA55 injection in light/medium COVID-19 patients
- Trial name
- NCT06042764
- Testing
- SA55 Injection
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
COVID-19
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19
AD17002 has demonstrated superior safety and efficacy as a nasal adjuvant function to an influenza vaccine in two completed clinical studies, and has innate immune modulatory and anti-inflammatory properties which could…
- Trial name
- NCT05069610
- Testing
- AD17002
- Where
- 2 sites in Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Advagene Biopharma Co. Ltd.
Covid19, Pneumonia
Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia
The purpose of this study is to evaluate the strategy of investigators for outpatients SARS-CoV-2 moderate pneumonia management in terms of efficacy and patient safety.
- Trial name
- PneumoCoV-Ambu (NCT04542044)
- Testing
- management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia
- Where
- Switzerland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Corona Virus Infection
Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection
This is a multi-center, randomized, controlled, phase II clinical efficacy study evaluating a novel Nitric Oxide Releasing Solution (NORS) treatment for the prevention and treatment of COVID-19 in healthcare workers at risk of…
- Trial name
- NOCOVID (NCT04337918)
- Testing
- NORS (Nitric Oxide Releasing Solution)
- Where
- 5 sites in Canada
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Sanotize Research and Development corp.
COVID 19, Thromboembolic and Bleeding Complications
Thromboembolic Complications in Mild Covid-19 Cases
The aim of the study is to investigate the frequency of thromboembolic complications and the factors influencing them in COVID-19 cases that did not require hospitalization.
- Conditions
- COVID 19, Thromboembolic and Bleeding Complications, Thromboembolism, Venous, Post COVID-19
- Trial name
- NCT06695377
- Where
- Turkey (Türkiye)
- Volunteers
- 961 people, healthy volunteers welcome
- Sponsor
- Marmara University Pendik Training and Research Hospital
Dementia, Mild Cognitive Impairment
Virtual Chair Yoga for Older Adults and Caregivers: Randomized Controlled Trial
Over 700,000 Canadians are affected by dementia costing the health care system approximately $10 billion/year. Due to COVID-19, the government has urged individuals over the age of 70 to stay home, putting this population at risk…
- Trial name
- NCT04884529
- Testing
- Chair-yoga program
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Lady Davis Institute
Covid19
At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
This is an open-label, pragmatic, single-dose study using matched controls in participants with mild to moderate COVID-19. Participants will track for developing symptoms while at home and upon reporting of symptoms will test for…
- Trial name
- UNITED (NCT04656691)
- Testing
- bamlanivimab
- Where
- United States
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Daniel Griffin
Covid19
Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients
COVID-19 is considered an ongoing international global health problem which already caused 12 million confirmed cases. No specific effective treatment has been identified so far, and available supportive therapies are intended…
- Trial name
- NCT04475120
- Testing
- liposomal lactoferrin, SOC therapy
- Where
- Italy
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- University of Rome Tor Vergata
Covid19
The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial)
Ivermectin, a classical antiparasitic and anti-scabies agent, has demonstrated antiviral activity for a variety of viruses including chikungunya virus, zyka virus and dengue virus and was tested as a potentially effective for…
- Trial name
- NCT04712279
- Testing
- Ivermectin 0.6mg/kg/day, Ivermectin 1.0mg/kg/day, Hydroxychloroquine
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Corpometria Institute
COVID-19
Plasma Immunity of Mild SARS-CoV-2 Omicron and Delta Pandemic in Thailand
The investigators assessed the effect of treatment for COVID and immunity of the volunteers who admitted to the home isolation.
- Trial name
- NCT05328479
- Where
- Thailand
- Volunteers
- 5,181 people, healthy volunteers welcome
- Sponsor
- Mahidol University
COVID, Sars-CoV2
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease
- Conditions
- COVID, Sars-CoV2, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
- Trial name
- NCT04419025
- Testing
- N-acetylcysteine
- Where
- 4 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Cambridge Health Alliance
COVID-19
A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19
This is a Phase 1/2 study evaluating the safety, tolerability and efficacy of IBI314.
- Trial name
- NCT05172141
- Testing
- IBI314(low dose), IBI314(high dose), IBI314(medium dose)
- Where
- China
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Mild-to-moderate COVID-19
Clinical Trial for Oral Formula of Vanillin and Wheat Germ Oil for Treatment of Mild and Moderate COVID-19 Viral Disease
The study is a randomized clinical trial to assess a natural formula of vanillin \& wheat germ oil to treat and stop the clinical progression of COVID-19.
- Trial name
- NCT05157139
- Testing
- Oral Capsule
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Alexandria University